What is it about?
Our study evaluated 119 luminal early breast cancer patients in whom preoperative Letrozole 2.5mg OD was given for a period of 2-4 weeks. The initial Ki67 was noted from the core biopsy specimen, and a post-therapy Ki67 value was obtained from the surgical specimen. The percentage fall was calculated and the factors affecting the same were analysed.
Featured Image
Photo by Angiola Harry on Unsplash
Why is it important?
Our study is one of the first of its kind in India, evaluating the response of different luminal early breast cancer patients to Letrozole therapy. This can help differentiate between good responders and poor responders to endocrine therapy, thus allowing us to tailor adjuvant therapy for each patient
Perspectives
We believe this study adds to the literature of similar trials which evaluate the fall in Ki67 after endocrine therapy, conducted in European countries. Our study maintains concordance with these studies, signifying that Ki67 should be addressed as a response assessment parameter, as opposed to a single value determinant of proliferation.
Dhanya Louis
Amrita Vishwa Vidyapeetham
Read the Original
This page is a summary of: Unchartered waters: Significance of fall in Ki67 index after short-term preoperative endocrine therapy in early breast cancers, Breast Disease, February 2023, IOS Press,
DOI: 10.3233/bd-220042.
You can read the full text:
Contributors
The following have contributed to this page
